ESSA Pharma Inc.
ESSA Pharma Inc.:
Focused on developing novel therapies for the treatment of prostate cancer. ESSA’s lead clinical candidate, EPI-7386 is an investigational, highly-selective, oral, small molecule inhibitor of the N-terminal domain of the androgen receptor. EPI-7386 is currently being studied in a Ph 1 clinical trial in men with metastatic castration-resistant prostate cancer whose tumors have progressed on current standard-of-care therapies. Initial data for Ph 1 monotherapy study of EPI-7386 is expected in 1H 2022. The company has also established clinical collaborations with JNJ, Astellas, and Bayer to evaluate EPI-7386 in combination with conventional anti-androgens. Combo trials remain on track to begin in Q4 2021 with RP2D already established.
Sector/Industry:
Healthcare/Biotechnology
Characteristics:
Based in...
North America
Clinical Stage
Phase l or ll, Pre-Clinical Stage
Disease Space
Men's Health, Oncology
Listing
Public, USA
Market Cap
100MM - 500MM
Website:
Profiles:
Address:
999 West Broadway Street Suite 720
Vancouver, BC BC V5Z 1K5
Canada
Vancouver, BC BC V5Z 1K5
Canada
More info:
My account:
Company Participants at Solebury Trout Hamptons CEO Roundtable 2021
- David Parkinson, President/CEO
Top 10 Holders of ESSA Pharma Inc
| Institution | OS (%) | Position | Mkt Val ($MM) | Source | Filing Date |
|---|---|---|---|---|---|
| Bellevue Asset Management AG | 11.34 | 4,990,714 | 28.45 | Stakes | 4/27/22 |
| Soleus Capital Management LP | 9.60 | 4,223,799 | 24.08 | 13F | 3/31/22 |
| Eventide Asset Management LLC | 9.47 | 4,170,259 | 23.77 | 13F | 3/31/22 |
| BVF, Inc. | 8.40 | 3,695,629 | 21.07 | 13F | 3/31/22 |
| Soleus Capital Management LP (Investment Management) | 8.02 | 3,525,457 | 20.10 | Stakes | 12/31/21 |
| Janus Henderson Investors US LLC | 7.83 | 3,444,894 | 19.64 | 13F | 3/31/22 |
| BVF Partners LP | 6.48 | 2,851,461 | 16.25 | Stakes | 12/31/21 |
| RTW Investments LP | 5.99 | 2,637,192 | 15.03 | 13F | 3/31/22 |
| Avidity Partners Management LP | 5.59 | 2,460,000 | 14.02 | 13F | 3/31/22 |
| Clarus Ventures LLC | 4.55 | 2,003,103 | 11.42 | 13F | 3/31/22 |
Ownership data is sourced through FactSet.
Stock Market Data
Data is being loaded...
Data is being loaded...
Data is being loaded...
Market Data copyright © 2022 QuoteMedia.
Data delayed 15 minutes unless otherwise indicated (view
delay times for all
exchanges). RT=Real-Time, RTB=Real-Time
BATS BZX Price/Quote; not sourced from all markets, RTN=Real-Time
NASDAQ Basic+ Price/Quote; not sourced from all markets, EOD=End of
Day, PD=Previous Day. Market Data powered by
QuoteMedia.
Terms of Use.